Abstract: The synthesis and application of N(1)-n-alkyl-pyrimidinium-salts are described. These surfactants have a very small critical micelle concentration (CMC) in the order of 10.sup.-5 -10.sup.-7 Mol/Liter. These N(1)-n-alkyl-pyrimidinium components have pharmacological activities and can act as antimetabolites.

Abstract: Powdered and/or granulated menadione sodium bisulfite formulations additionally contain a physiologically tolerated organic or inorganic acid.The novel formulations possess good water solubility and stability.

Abstract: Proteins having substantially the same biological activity as PDGF are provided. In one aspect, a protein homodimer having two polypeptide chains is disclosed, each of the chains being a mosaic of amino acid sequences substantially identical to portions of the A- and B-chains of PDGF, the protein being chemotactic or mitogenic for fibroblasts. Therapeutic compositions comprising such proteins in combination with a physiologically acceptable carrier or diluent are also provided. Such therapeutic compositions may be used within methods for enhancing the wound-healing process in warm-blooded animals.

Abstract: Compositions comprising a calcitonin gene related peptide and, as an absorption enhancer, a glycyrrhizinate.

Abstract: Ascorbic acid composition comprising a trace amount of an alkli metal compound or an alkaline earth metal compound is very stable with respect to coloring and does not acquire a yellow color even after along time storage.The composition can be easily obtained by addition of only a trace amount of an additive.

Abstract: The invention relates to a solid phospholipid composition with a high phosphatidylcholine content which, in addition to the corresponding phospholipids, contains Palatinit and if appropriate one or more other auxiliaries, and a process for its preparation and its use as an oral presentation form.

Abstract: A composition and method for nasal administration of pharmaceuticals utilizes glycyrrhetinic acid as an absorption enhancer. The composition comprises an effective amount of the pharmaceutically active substance, glycyrrhetinic acid, in an amount effective for enhancing permeation of the active substance across the nasal membrane, and a basic salt of an amino acid as an adjuvant. The composition may be administered to the nasal cavity in the form of a spray by using an atomizer, nebulizer, spayer, dropper or other device which ensures contact of the composition with the nasal mucus membrane.

Abstract: Use of modified diorganopolysiloxanes as antioxidants in cosmetics or in dermatology.Use, as an antioxidizing agent in cosmetics or in dermatology, of diorganopolysiloxanes (i) of formula (I): ##STR1## in which the symbols R denote alkyl or phenyl, B are chosen from the radicals R and A, a an integer chosen between 0 and 200 inclusive, b an integer chosen between 0 and 50 inclusive, and if b is equal to 0, at least one of the two symbols B is A,A is of formula: ##STR2## where: R.sub.1 denotes hydrogen or an alkyl,R.sub.2 denotes hydrogen, hydroxyl, alkyl or alkoxy,R.sub.3 denotes hydrogen, hydroxyl or alkyl,R.sub.4 denotes hydrogen or alkyl,R.sub.5 denotes hydrogen, hydroxyl or alkoxy,Y denotes:(O).sub.n --CH.sub.2 --CH(R.sub.6)--CH.sub.2 --whereR.sub.6 denotes hydrogen or alkyl and n has the value of 0 or 1,or (ii) of formula (II): ##STR3## where c is an integer between 1 and 20 inclusive,d is an integer between 2 and 20 inclusive, andc+d equal to or greater than 3.

Abstract: A stable pharmaceutically acceptable formulation containing a pharmaceutically acceptable amount of a protein is disclosed. Also disclosed are associated means and methods for preparing such formulations.

Abstract: A stable pharmaceutically acceptable formulation containing human growth hormone, glycine, mannitol, a buffer, and optionally, a non-ionic surfactant is disclosed. The formulation contains human growth-hormone: glycine in 1:50-200 molar ratios. Also disclosed are associated means and methods for preparing and using such formulations.

Abstract: Aqueous stable injectable formulations containing the sodium salt of naproxen, stabilizing agents and polyhydroxylic alcohols, packaged in containers made up of boxes of polystyrene or of an equivalent material covered with films which absorb the light radiations.

Abstract: An ointment comprising an adenosine 3',5'-cyclic phosphate derivative as an active ingrediment, an ointment base having water-absorbing and drying properties, a saccharide and/or inorganic high polymer is disclosed. The ointment exhibits improved stability of the adenosine 3',5'-cyclic phosphate derivative.

Abstract: The pharmaceutical composition of the invention, which comprises a benzimidazole compound of the formula ##STR1## wherein R.sup.1 hydrogen, alkyl, halogen, cyano, carboxy, carboalkoxy, carboalkoxyalkyl, carbamoyl, carbamoylalkyl, hydroxy, alkoxy, hydroxyalkyl, trifluoromethyl, acyl, carbamoyloxy, nitro, acyloxy, aryl, aryloxy, alkylthio or alkylsulfinyl, R.sup.2 is hydrogen, alkyl, acyl, carboalkoxy, carbamoyl, alkylcarbamoyl, dialkylcarbamoyl, alkylcarbonylmethyl, alkoxycarbonylmethyl or alkylsulfonyl, R.sup.3 and R.sup.5 are the same or different and each is hydrogen, alkyl, alkoxy or alkoxyalkoxy, R.sup.4 is hydrogen, alkyl, alkoxy which may optionally be fluorinated, or alkoxyalkoxy, and m is an integer of 0 through 4, and a basic inorganic salt stabilizing agent, is physically stable. Magnesium and calcium basic inorganic salt stabilizing agents are particularly useful.

Abstract: Temperature stable 5-fluorouracil compositions are disclosed. A solution of 5-fluorouracil and a base forms the composition. The pH of the composition is about 9.1 to about 9.3. The composition is less prone to precipitate at temperatures below 60.degree. F.

Abstract: The invention provides a stabilized aqueous solution of a water soluble pentamidine salt comprising an acetate buffer, and having a total acetate concentration of 0.01-0.06M, and a pH of 4.0-5.0 at room temperature.

Abstract: A cosmetic product is disclosed in the form of a gelatin walled capsule encompassing a cosmetic composition that includes a carrier which is a silicone polymer and an antioxidant. The antioxidant operates to inhibit degradation of the gelatin wall to prevent malodors from being generated. Retinoic acid derivatives such as retinyl palmitate are especially effective as antioxidants.

Abstract: The present invention is a pharmaceutical composition for proteins which are not stably soluble. The preferred protein is IL-2 and the preferred composition includes amino acids, vitamins, polymers, fatty acids or low molecular weight acids.

Abstract: The present invention pertains to an edible coated composition which comprises (a) a core material comprising sorbitol, (b) a primary coating layer comprising zein over the core material, and (c) a sugarless secondary coasting layer over the primary coating layer. The present invention also pertains to methods for preparing the edible coated compositions.

Abstract: A process for stabilizing attenuated lyophilized vaccines with a compound having the general formula: ##STR1## wherein R1 is an oxygen atom or a sulphur atom and R2 is a NH.sub.2 group or a linear chain, unsaturated or not, selected from the group consisting of --O--C . . . , --NH--C . . . , and --C . . . .

Abstract: Stabilized antimicrobial compositions containing an antimicrobial amount of 2,2-dibromo-3-nitrilopropionamide in water miscible organic solvents. The stabilizer used is selected from chain-breaking antioxidants of the phenolic or amine type in an amount in the range of 0.001% to 0.5% by weight of the composition. Typical examples of stabilizers are: 2,6-di-tert-butyl-p-cresol; 4,4'-bis-(2,6-di-tert-butylphenol); 2,6-di-tert-butyl-.alpha.-methoxy-p-cresol and N-phenyl-.beta.-naphthylamine. The antimicrobial compositions also contain one or more water miscible organic solvents selected from those known in the art, in which the 2,2-dibromo-3-nitrilopropionamide is at least partially soluble. The compositions according to the present invention are characterized by their outstanding stability, compared with formulations which do not contain these stabilizers.

Abstract: The fibrous polymeric material based on polyvinyl chloride contains at least one antiseptic mercury derivative distributed in its polymeric structure in the form of a substantially molecular and practically non-releasable dispersion.The preferred mercury derivatives have the following general formula: ##STR1## in which Y is H or HgX. If the concentration of the derivative is equal to at least 0.5% by weight, relative to the chlorofiber, the latter has a permanent antiseptic character.This material is obtained by incorporating the above-mentioned derivative into the collodion when the chlorofiber is spun.

Abstract: A nasal administration powder composition containing a physiologically active peptide as an active ingredient can be efficiently absorbed through nasal mucosa by the addition of a water-soluble organic acid as an absorption promoter. This composition may further contain a diluent. The water-soluble organic acid used as absorption promoter includes, for example, at least one of succinic acid, tartaric acid, citric acid, fumaric acid, maleic acid, malonic acid, glutaric acid, adipic acid, malic acid, L-glutamic acid, L-aspartic acid, gluconic acid and glucuronic acid.

Abstract: The synthesis and application of N(1)-n-alkyl-pyrimidinium-salts are described. These surfactants have a very small critical micelle concentration (CMC) in the order of 10.sup.-5 -10.sup.-7 Mol/Liter. These N(1)-n-alkyl-pyrimidinium components have pharmacological activities and can act as antimetabolites.

Abstract: The present invention provides stable pharmaceutical compositions containing disodium adenosine triphosphate (ATP-2Na) which are advantageous in that, as a result of the addition of a low-melting fat- or oil-like substance to ATP-2Na, the decomposition or the like of ATP-2Na is prevented and the content of ATP-2Na can be maintained at a high level even after the lapse of a number of days.The compositions according to this invention can be used advantageously, for example, in the treatment of cerebrovascular disorder, cardiac failure and asthenopia.

Abstract: The present invention relates to an intravenous pharmaceutical composition comprising cyclosporin as active ingredient. The composition is composed ofa) 1 part by mass of one or more cyclosporins,b) 8 to 13 parts by mass of a monoester of a saturated hydroxylated fatty acid formed with polyethylene glycol or the mixture of said monoesters,c) 4 to 10 parts by mass of one or more intravenously administerable mono- or polivalent alcohols.The invention further relates to a process for preparing such composition.

Abstract: Small unilamellar liposomes (d<600 nm) comprising an unsaturated phosphatidylethanolamine (PE) such as dioleoyl PE (DOPE) and a fatty acid such as oleic acid (OA) are stabilized by adding to a freshly prepared liposome suspension, an amphipile which has a high tendency to form micelles. Examples are shown for the following micelle-forming amphiphiles: lysophospholipide, gangliosides (GM.sub.1 and GTlb), sulfatide, synthetic glycopholipids such as sialo-lactosyl phosphatidylethanolamine, liopohilic drugs such as cytosine arabinoside diphosphate diacyglycerol, and proteins such as cytochrome b.sub.5, human high density lipoprotein (HDL), and human glycophorin A. The stabilized liposomes are resistant to the lytic action of albumin, the major blood component which causes the lysis of this type of liposome. Prior to the present invention, liposomes comprising PE and OA were typically stabilized by the incorporation of cholesterol.

Abstract: Stable pharmaceutical compositions suitable for parenteral administration to animals or humans are prepared comprising a therapeutically effective amount of a recombinant interleukin-2 (IL-2) protein dissolved in an inert carrier medium comprising one or more biocompatible non-ionic polymeric detergents which act as solubilizer/stabilizers for the claimed formulations.

Abstract: Disclosed are novel, stable pharmaceutically acceptable compositions containing human tissue plasminogen activator, featuring, for example, an argininium ion containing buffer as a component. Also disclosed are associated means and methods for preparing and using such compositions in various forms.

Abstract: A stabilized pharmaceutical composition which is an admixture of an NSAID selected from diclofenac and piroxicam, a prostaglandin and hydroxypropyl methylcellulose for maintaining the prostaglandin in a therapeutically effective amount without negatively affecting the therapeutic activity of the NSAID.

Abstract: A pharmaceutical composition which comprises a mixture of an alpha-2 adrenoceptor antagonist, preferably idazoxan, or a pharmaceutically acceptable salt thereof, and either a catecholamine precursor or carbidopa.

Abstract: A method of reducing or eliminating adverse effects of a pharmaceutical composition or a drug is disclosed. The method comprises administering to an animal or a human an amount of at least one specific isomer of inositol triphosphate sufficient to reduce or eliminate said adverse effects.

Abstract: Novel catecholamine solutions for physiological uses are provided at a pH in the range of 1.0-5.0, comprising catecholamine, acetylcysteine, chelating agent and buffering agents. The compositions are stabilized from oxidation without the use of sulfites and are preferably administered by inhalation.

Abstract: An improved process for recovering and purifying lipophilic recombinant proteins such as human .beta.-interferon and interleukin-2 from their hosts yields a protein preparation which may be formulated into a stable pharmaceutical composition having a therapeutically effective amount of the biologically active recombinant lipophilic protein dissolved in a non-toxic, inert, therapeutically compatible aqueous-based carrier medium at a pH of 6.8 to 7.8 which medium also contains a stabilizer for the protein, such as human serum albumin, normal serum albumin and human plasma protein fraction.

Abstract: A compatible, storage-stable human protein preparation containing a human protein, a physiologically compatible buffer and optionally complex formers, isotonia-adjusting agents, calcium chloride and other materials usual for injection purposes which, in an injectable form, contains 5 to 50 g./liter urea, 1 to 50 g./liter amino acid and 0.05 to 5 g./liter non-ionic wetting agent. A process for the production of this preparation is also disclosed.

Abstract: Stable cosmetic compositions comprising ascorbic acid dissolved in at least two co-solvents, one of which comprises water, the other of which comprises an organic solvent miscible with water, or a blend of water miscible organic solvents. The compositions are adapted to be topically applied to the skin to impart appearance benefits thereto.

Abstract: The present invention provides an aqueous solution composition containing elcatonin as an active ingredient used for hypercalcemia or bone Paget's disease or improvement of pain in osteoporosis, etc. and which is highly stable against shaking, light and heat. This composition contains an effective amount of elcatonin as an active ingredient and a monocarboxy compound and/or its water soluble salt thereof in a molar concentration of 0.05-20 mmol and has a pH of 5.0-6.5 and an ionic strength of .mu.=0.01-0.5. Preferred examples of the monocarboxy compound and its salts are acetic acid, lactic acid, L-histidine, sodium acetate, potassium acetate, sodium lactate, potassium lactate and L-histidine hydrochloride.

Abstract: There is provided a shelf stable solution of aspirin, free of moieties reactive with aspirin, suitable for topical application to the skin compounded from aspirin, N,N-diethyl-m-toluamide USP (DEET), glyceryltriacetate USP (GTA), and acetic anhydride, provided that where GTA is present, at least 20 parts of DEET shall also be present and, after all components shall have been mixed, the resultant solution shall contain an initial amount of between about 1 and about 0.2 parts of acetic anhydride. The solution is made by preparing a solvent component consisting of at least N,N-diethyl-m-toluamide USP (DEET), and, if desired, glyceryltriacetate USP (GTA), provided that where GTA is present, at least 20 parts of DEET shall also be present, assaying said solvent mixture to determine the hydroxyl content, adding sufficient acetic anhydride to provide between about 1 and about 0.2 parts of unreacted acetic anhydride in the solution after dissolution of the aspirin therein, and dissolving aspirin, thereinto.

Abstract: The present invention is directed to a stable, rapidly soluble lyophilized injectable composition containing up to about 6% moisture and capable of being stored at room temperature comprising the hydrochloric or sulfate salt of a compound selected from the group consisting of (S)-(+)-bis-4,4'-(1-methyl-1,2-ethanediyl)2,6-piperazinedione and (R)-(-)-bis-4,4'-(1-methyl-1,2-ethanediyl)2,6-piperazinedione; wherein said lyophilized composition is prepared from a bulk solution comprising from about 25 mg/mL to about 40 mg/mL of said compound dissolved in a hydrochloric acid or sulfuric acid; wherein the pH of said bulk solution is from about 1.0 to about 2.0. The invention is further directed to an isotonic solution which is formed upon reconstitution of the lyophilizate of the invention with a pharmaceutically acceptable diluent.

Abstract: A stable soothing hydroalcoholic skin preparation for shaving purposes employing alcohol as a carrier or solvent for the remainder of the composition comprising a combined allantoin-boric acid hydrolyzed solution in combination with glycerine, menthol, ethyl alchohol and fragrance.

Abstract: Growth hormone releasing factor (GRF) preparation which is excellent in stablity by having human serum albumin or glycine incorporated therein, with or without buffer. An amount of human serum albumin or glycine contained is usually 100 .mu.g to 30 mg per 100 .mu.g GRF. The preparation may be in the solid or solution form, preferably in the lyophilized form. An amount of buffer, if added, is preferably enough so that pH of the preparation is kept at 2-7. More preference is that the preparation is kept in nitrogen gas atmosphere. The lyophilized preparation is readily usable for, for example, injection.

Abstract: An aqueous solution comprises lysozyme hydrochloride, dipotassium glycyrrhizinate, at least one selected from the group consisting of sodium chloride, potassium chloride, calcium chloride, magnesium chloride, sodium phosphate, potassium phosphate, sodium citrate, potassium citrate, sodium carbonate and potassium carbonate and water, has a pH of 5 to 9 and is useful for eye drops.

Abstract: Storage stable aqueous ophthalmic, substantially isotonic solutions of pharmaceutically acceptable salts of ortho-(2,6-dichlorophenyl) aminophenylacetic acid, and having a pH of about 7.0 to about 7.8, comprising per ml solution:(a) about 0.1 to about 5.0 mg of a pharmaceutically acceptable salt of ortho-(2,6-dichlorophenyl)aminophenylacetic acid;(b) about 0.1 to about 10 mg of a pharmaceutically acceptable salt of ethylenediamine tetraacetic acid;(c) about 0.5 to about 200 mg of a pharmaceutically acceptable solubilizer;(d) about 0.01 to about 5.0 mg of a pharmaceutically acceptable bacteriostat; and(e) the remainder water,and the use of such solutions, by topical administration to the eye of a warm blood mammal, for the control or treatment of ocular inflammation.

Abstract: A pasteurized human firbinogen which can be used therapeutically, and a process for its preparation are described.

Abstract: The present invention relates to a solution for dialyses based on bicarbonate ions and containing a peptide based on glycine, as well as to the use of this peptide for the preparation of such a solution.

Abstract: The invention relates to a plant-protective solution containing 2.5 to 40 % by weight of one or more water-insoluble plant-protective ingredient(s) 20 to 71.5 % by weight of dimethylformamide and/or dimethylsulfoxide and/or acetone as water-miscible solvent, 10 to 71.5 % by weight of furfurol and/or furfuryl alcohol as partially water-miscible solvent, 1 to 15 % by weight of commonly used additives such as anionic and/or nonionic surface active agents and macromolecules.The invention also relates to the ready-for-use plant-protective suspension containing 0.2 to 10 % by weight of one or more water-insoluble plant-protective ingredient(s) with a particle size of 0.1 to 50 .mu.m, 0 to 60 % by weight of a fertilizer, 0.2 to 10 % by weight of dimethylformamide and/or dimethylsulfoxide and/or acetone as water-miscible solvent, 0.2 to 10 % by weight of furfurol and/or furfuryl alcohol as partially water-miscible solvent, 0.05 to 2.

Abstract: Stabilized staining solutions are provided which comprise dyes and a combination of dimethylammonium sulfate and crystallization inhibitors. The staining solutions are used for staining in hematology, cytology and histology.

Abstract: There are disclosed a recombinant interleukin-2 composition consisting essentially of water, recombinant interleukin-2, and optionally a polyol, said composition having a specific activity of at least about 120,000 units/mg and a process for preparing it by heating a suspension of the interleukin-2 at a specified temperature.

Abstract: The addition of nonionic surfactants to aqueous pyrethroid insecticidal formulations increases the pyrethroid stability when the formulation is stored in a polyvinylchloride (PVC) container. The pyrethroids can be synthetic or naturally occurring pyrethroids. The nonionic surfactants are alkylphenol ethoxylates, ethoxylated primary alcohols, polyoxyethylene thioethers or mixtures thereof and have HLB values of between about 10 and about 14.

Abstract: A urine specimen is preserved from bacterial deterioration as to relative constituents by adding thymol. To the thymol-treated specimen, lithium-solution volume-marker is added, then is divided into two (first and second) separate portions. Thereupon, using the first portion, standard conventional measurements and/or analysis is conducted for total volume, pH/acidity, uric acid, citrate, sodium, and potassium. To the second portion, there is added boric acid and hydrochloric acid, followed by standard/conventional measurement and/or analysis for ammonium ion, citrate, calcium, magnesium, phosphorus, oxalate and sulfate. Thereafter the findings are charted and compared to controls.

Abstract: An oral composition for preventing periodontal diseases through suppression of the colonization of causative bacteria of periodontal diseases comprises an antibody obtained by immunizing a mammal with at least one antigen selected from the group consisting of periodontal causative bacteria, their pilus and capsule fractions, and aluminum hydroxide for stabilizing said antibody.